In a world where profit is the bottom line and greed is re-labeled as “ambition”, here are some factors to consider why the system in a loose general way doesn’t design cures, rather finds it more profitable to provide treatments instead:

1. Continuous Revenue Stream: Treatments often involve ongoing or regular purchases of medication, therapies, or medical devices. This creates a continuous revenue stream for pharmaceutical companies and healthcare providers.
2. Recurring Sales: Chronic conditions or diseases that require long-term management generate recurring sales for companies. This contrasts with cures, which might result in a one-time treatment and a loss of future revenue for that particular condition.
3. Patent Protection: Companies can obtain patents for specific treatments, allowing them to have a monopoly on the market for a certain period. Cures, on the other hand, might not be patentable or might have shorter patent protection, reducing the exclusivity period for profit generation.
4. High Development Costs: Developing a cure can be a lengthy and expensive process involving extensive research and clinical trials. Companies may find it more financially viable to focus on treatments that can be brought to market more quickly and with lower development costs. (Although this could potentially happen, it is just as likely that although the cost of a given treatment might be more expensive to develop than a cure; the treatment can be many times more profitable than the cure, making it long-term more desirable than a cure from an investment standpoint.
5. Insurance and Healthcare System Dynamics: In some healthcare systems, insurance companies and healthcare providers may have financial incentives tied to ongoing treatments. The structure of these systems may discourage the development or promotion of cures.
6. Market Demand: Treatments often cater to a larger market since they address ongoing health concerns that affect a significant portion of the population. Cures may be developed for conditions that affect a smaller subset of individuals, potentially limiting their market size. Symptoms can often be shared between maladies, so developing mildly affective treatments that cover a wider range of causes towards similar symptoms is a blanket coverage model of addressing the largest possible groups of people.
7. Consumer Behavior: Consumers may be more inclined to seek treatments that provide relief from symptoms in the immediate short-term rather than opting for cures, especially if the latter involves higher upfront costs or potential side effects, unless the problem is acutely persistent and aggravating and/or painful.

It’s important to note that the profit motive in healthcare can have ethical implications, especially when it seems to prioritize financial gains over the well-being of individuals and the good of the collective whole of society. It is not then a surprise that a company or corporation will build a system that despite the moral incapacity, will inevitably be more profitable. These are the systems that have been preying on the majority of society for many years, decades and in the case of some systems…..centuries.